Related by context. All words. (Click for frequent words.) 58 INC. SELECTED FINANCIAL DATA 53 EOG RESOURCES INC. 53 INCOME STATEMENT 53 SUBSIDIARIES 53 -Tomine 53 UNAUDITED CONSOLIDATED BALANCE SHEETS 53 INC. UNAUDITED CONDENSED CONSOLIDATED 53 * Reclassified 53 SUBSIDIARIES Supplemental 53 AND SUBSIDIARIES Condensed Consolidated 52 STATEMENTS OF 52 Qtr Qtr Qtr Qtr 52 PER SHARE AMOUNTS 52 #,# NOVA MEASURING 51 =America Airline Satisfaction 51 FINANCIAL AND OPERATIONAL 51 -ANDREA SACHS 51 DATA unaudited 51 ITS SUBSIDIARIES CONDENSED CONSOLIDATED 51 2nd Qtr 1st Qtr 51 GAAP FINANCIAL INFORMATION 51 TO NON GAAP MEASURES 51 -ABGL 51 YTD YTD 51 QUARTER TO DATE 51 GAAP TO ADJUSTED 51 SUBSIDIARIES Consolidated Statements 51 Fourth Quarter Twelve Months 50 FINANCIAL RESULTS RECONCILIATION OF 50 Unaudited Pro Forma 50 GAAP NON GAAP 50 ROLLINS INC. AND SUBSIDIARIES 50 STATEMENTS OF EARNINGS 50 YEAR ENDED DECEMBER 50 CONSOLIDATED SUBSIDIARIES CONDENSED CONSOLIDATED 50 Change - [011] 50 Condensed Cash Flow 50 Change - [003] 50 IFRS IFRS 50 OF OPERATIONS AND COMPREHENSIVE 50 HUMAN SCIENCES INC. Condensed 50 4th Qtr 3rd Qtr 50 OF SEPTEMBER 50 SUBSIDIARIES Condensed Consolidated Statements 49 OPERATIONS Amounts 49 Constant Currency 49 THREE MONTHS ENDED DECEMBER 49 AND SUBSIDIARIES 49 Contained Metal 49 RMB RMB 49 USGAAP 49 = [028] 49 Pro Forma Net 49 SELECTED FINANCIAL AND 49 AMOUNTS IN THOUSANDS EXCEPT 49 Audited Unaudited 49 STATEMENTS OF OPERATIONS UNAUDITED 49 = [044] 49 FINANCIAL INFORMATION UNAUDITED 49 TWELVE MONTHS ENDED DECEMBER 49 CONDENSED CONSOLIDATED INCOME STATEMENTS 49 STATEMENTS OF EARNINGS Unaudited 49 Third Quarter Nine Months 49 NON GAAP RECONCILIATION 49 Comparative Figures 49 STATEMENT OF OPERATIONS 49 Q# Q# Q# 49 Certain comparative 49 OF OPERATIONS THREE MONTHS 49 AND COMPREHENSIVE INCOME 49 CONDENSED STATEMENT OF OPERATIONS 48 Months Months 48 OF EARNINGS UNAUDITED 48 -Keops 48 = [026] 48 PRO FORMA 48 = Per [007] 48 COMPANY CONSOLIDATED INCOME STATEMENTS 48 FINANCIAL SUMMARY 48 Adjusted Non GAAP 48 EOG RESOURCES INC. SUMMARY 48 STATEMENTS OF FINANCIAL POSITION 48 CONSOLIDATED STATEMENT OF 48 CONSOLIDATED STATEMENT OF INCOME 48 PRO FORMA RESULTS 48 AND SUBSIDIARIES Consolidated Statements 48 -Kaloki 48 SOUTHWEST BANCORP INC. 48 Incr 48 OPERATING RESULTS 48 OPERATIONS UNAUDITED 48 Six Months Six Months 48 QUARTERS ENDED 48 Equivalent 48 Sheets Unaudited 48 No. #R Consolidation 48 SEGMENT INFORMATION 48 -Soft soled shoes 47 Supplemental Non GAAP 47 YEAR TO DATE 47 Historical Pro Forma 47 - Revenues [006] 47 GAAP FINANCIAL MEASURES 47 Q#/# Q#/# [001] 47 -FALL CAMP 47 Three Months Twelve Months 47 GAAP ments 47 equivalents 47 FINANCIAL MEASURES 47 -Andrea Seabrook 47 Supplementary Data 47 AND OTHER COMPREHENSIVE INCOME 47 FINANCIAL STATEMENTS 47 -Lighting Designers 47 SUBSIDIARIES BUSINESS SEGMENT 47 UNAUDITED Amounts 47 Quarters Ended Six Months 47 POLYCOM INC. GAAP 47 Foreign Currency Translation 47 #Q# #Q# Change [001] 47 OF FINANCIAL CONDITION 47 SUMMARY OF RESULTS 47 GAAP Adj 47 unaudited unaudited unaudited 47 STATEMENTS OF CONSOLIDATED INCOME 47 Twelve Months Ending 47 TO FUNDS FROM 46 Six Months Months 46 CONSOLIDATED RESULTS 46 FINANCIAL RESULTS 46 STATISTICS Unaudited 46 unaudited audited 46 OF INCOME unaudited 46 AND PRO FORMA 46 SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS 46 -AL Gustin 46 unaudited unaudited 46 -Peter Van Keuren 46 Qtr Ended 46 OPERATING HIGHLIGHTS 46 INCOME UNAUDITED 46 PERCENT CHANGE 46 # -b Reflects 46 SELECTED RATIOS 46 -Quarriers 46 -Elmers 46 STATEMENTS OF OPERATIONS 46 # -GT2 RS 46 PIONEER DRILLING COMPANY 46 HIGHLIGHTS UNAUDITED 46 SUBSIDIARIES Consolidated Balance Sheets 46 Compositional 46 AND COMPREHENSIVE INCOME Unaudited 46 - RevGreencool 46 - ASSETS [014] 46 Adjustment Non GAAP 46 TRICO MARINE SERVICES INC. 46 Second Quarter Six Months 46 ODYSSEY HEALTHCARE INC. AND 46 Cash Flow Statements 46 Unaudited Unaudited Unaudited Audited 46 AND FUNDS FROM 46 Fourth Quarter Ended Twelve 46 unaudited - 46 AND SUBSIDIARIES Segment 46 Computations 46 NON GAAP FINANCIAL INFORMATION 46 SUBSIDIARIES Consolidated Statement 46 CONSOLIDATED BALANCE SHEET UNAUDITED 45 -Name Directory DND 45 -Raghavendra Rathore 45 -dwayne tingley 45 Non Gaap 45 OF EARNINGS Unaudited 45 Quarter Ended Nine Months 45 Twelve Twelve Months 45 unaudited Nine Months 45 retrospectively adjusted 45 3rd Qtr 2nd Qtr 45 INC. Supplemental 45 Selected Balance Sheet 45 DCT INDUSTRIAL TRUST INC. 45 WESTWOOD ONE INC. SUPPLEMENTAL 45 Unaudited Third Quarter 45 Three Month Periods 45 # -loudly protested 45 MONTHS ENDED 45 OPERATING AND 45 SMITHFIELD FOODS INC. AND 45 - Unaudited [013] 45 UNAUDITED 45 Non GAAP Measure 45 RMB RMB USD 45 Taxable equivalent 45 UNAUDITED THREE MONTHS ENDED 45 Summary Balance Sheet 45 Seasonally Adjusted 45 Quarters Ended Nine Months 45 Test Methodology 45 Comparative Condensed Consolidated Statements 45 isotope dilution 45 -Kahaani Ghar Ghar Ki 44 Third Quarter Ended Nine 44 Animal Feed Additives 44 EARNINGS SUMMARY 44 Unaudited Twelve Months 44 # -DiBacco 44 Quarters Ended Years 44 -tiger muskies 44 RESULTS OF OPERATIONS 44 -Hua Tian 44 Nine Months Nine Months 44 Financial Ratios 44 BROOKLINE BANCORP INC. AND 44 - -SIRTI 44 BALANCE SHEETS Unaudited 44 FINANCIAL INFORMATION 44 Stent Placement 44 Three Months EndedDecember 44 Unaudited Quarter Ended 44 HIGHLIGHTS Three Months 44 NINE MONTHS ENDED SEPTEMBER 44 Balance Sheet Cash Flow 44 Dry Powder Inhalers 44 CITIZENS FINANCIAL SERVICES INC. 44 IBERIABANK CORPORATION CONDENSED CONSOLIDATED 44 Non IFRS 44 DOI #.# 44 Adjust Non GAAP 44 -SEAMUS BRENNAN 44 SUMMARY RESULTS 44 Percent Percent 44 Unaudited Fourth Quarter 44 GBPm 44 #.#.# [037] 44 Quarter Ended #/#/# #/#/# [002] 44 GLOSSARY OF TERMS 44 CrossRef Medline 44 Three Months Nine Months 44 unaudited Amounts 44 -Przybyl 44 Prolongs Survival 44 Unaudited Condensed Consolidated 44 #:#-# [006] 44 Condensed Income 43 Pro Forma Adjusted 43 Unfav 43 Quarter Quarter Ended 43 -Edna Hibel 43 Unaudited 43 UNITED MICROELECTRONICS CORPORATION 43 3rd Qtr 4th Qtr 43 -firewall router 43 III #Table 43 -gangplanks 43 Cash Flow Margin 43 Comparative Analysis 43 Adjusted Diluted EPS 43 Bulk density 43 GAAP Measures 43 Three Months Ending 43 MINDRAY MEDICAL INTERNATIONAL LIMITED 43 Unaudited -immanent 43 SIGNIFICANT ACCOUNTING POLICIES 43 - Babelgum Online 43 Percentage Change 43 - unaudited [008] 43 Clinical Outcome 43 Pt Chg 43 polygonal method 43 IEC #-# [001] 43 -Edgewater Networks 43 UNAUDITED Three Months 43 #:#-# [037] 43 -Tyrell Fenroy 43 Wheat Starch 43 Visualization Equipment 43 -#.# pp [002] 43 FTE headcount Three Months 43 HERTZ GLOBAL HOLDINGS INC. 43 unaudited unaudited -watchdog BaFin 43 FUND Consolidated Statements 42 Correlated 42 Fourth Quarter Ended 42 #:#-# [027] 42 Unaudited Amounts 42 MANAGEMENT DISCUSSION AND ANALYSIS 42 Analytical Methods 42 Alloying 42 Summary Table 42 Supplemental Table 42 Yr Yr 42 CFS BANCORP INC. 42 unaudited Three Months 42 Three Months Months Ended 42 Pharmacokinetic parameters 42 Normalized 42 Fab Wafer 42 Year Ended Ended 42 Various Types 42 J Pediatr 42 Measurement Uncertainty 42 κ 42 Inflammatory Pain 42 Unaudited Unaudited Audited 42 Predecessor Successor 42 Definitions 42 SUMMARY TABLE 42 Per Per 42 retroactively restated 42 #-#/# [022] 42 Change - [002] 42 Three Months Six Months 42 Tabular 42 #:#-# [022] 42 -Restart 42 AND SUBSIDIARIES SEGMENT REPORTING 42 3rd edn 42 Neural Networks 42 -hip shakin 42 Segment Operating 42 Protein Synthesis 42 Segmental 42 β carotene 42 EXECUTIVE SUMMARY 42 Oilfield Chemicals 42 #.#c #.#c [002] 42 Pro Forma Non GAAP 42 FINANCIAL OVERVIEW 42 EBITDA Calculation 42 Determinant 42 Ended Twelve Months Ended 42 #:#-# [014] 42 - -Rough Sleepers 42 Randomized Phase II 42 -sodium chloride 42 unaudited -Nesha Starcevic 42 Highlights Unaudited 42 Statistical Tables 42 -6News Jennifer 42 Comparative 42 Conformational 42 REAL ESTATE BUSINESS 41 mean ± SEM 41 Selected Operating 41 Rosiglitazone Evaluated 41 Unaudited Dollars 41 Clinical Implications 41 1st Qtr 2nd Qtr 41 -Amneal Pharmaceuticals LLC 41 Unaudited Consolidated 41 - -Lofoten Islands 41 Pro Forma Results 41 Income Unaudited Amounts 41 Supplementary Table 41 Main Outcome Measures 41 GULF RESOURCES INC. AND 41 multivariable Cox 41 General Accepted Accounting 41 Competitive Positioning 41 Mineral Resource estimation 41 LIST OF TABLES Table 41 #:#-# [019] 41 Adjusted EBITDAX 41 Modulates 41 Six Months Ended -Ronald Moten 41 variograms 41 SUBSIDIARIES Condensed Consolidated 41 -prosumer 41 Tabular amounts 41 Controlled Trial 41 Month Period Ended 41 Competitive Scenario 41 Pooled Analysis 41 Unaudited Thirteen 41 #Table [003] 41 reclassed 41 Factors Influencing 41 Generally Accepted 41 retrospectively restated 41 - Unaudited [015] 41 Susceptibility Testing 41 Placebo Controlled Trial 41 g cc 41 #Q# #Q# Var 41 intraclass correlation coefficient 41 Homogeneous 41 Clinical Evaluation 41 Postdoctoral Position 41 Non GAAP Disclosures 41 using ordinary kriging 41 kinematic viscosity 41 -Coco Reef 41 Year Ended 41 Comparable EBITDA 41 Therapeutic Efficacy 41 Unaudited Reconciliation 41 Prevalence Worldwide 41 #:#-# [023] 41 Unaudited CANADIAN 41 Bioavailability 41 mmcf equivalent 40 - Adjusted [018] 40 SUMMARY DATA SHEET 40 Isotopic 40 Per Share Quarter Ended 40 Standardized Distributable Cash 40 Quarter Ended Quarter Ended 40 Consolidated Cash Flows 40 Seriously Flawed 40 Prolongs Life 40 Not Meaningful 40 Reconciliation Tables 40 Meta Analysis 40 Condensed Consolidated Interim 40 Antitumor 40 '#s except 40 LIST OF FIGURES 40 Three Months Ended Twelve 40 DISCOVERY HOLDING COMPANY 40 Reproducibility 40 Multivariate 40 MarketAxess Announces 40 Reported Adjustments Non GAAP 40 Reclassified 40 Nucleic Acid Amplification 40 Invasive Fungal Infections 40 Sensitivity Analysis 40 Monte Carlo Simulation 40 Cancer Res 40 READER ADVISORY 40 Currency Translation 40 Randomized Clinical Trials 40 Imaging Techniques 40 Consolidated Condensed Statement 40 Q3 YTD 40 Restruc 40 Ended -Agility SAP 40 -T#/T# 40 Analyte 40 Mathematical Statistics 40 2nd Qtr '# 40 S. pombe 40 CdSe 40 Randomized Trials 40 B.1 40 Debt Ratios 40 Pro forma 40 Calculation 40 tabular amounts 40 Logistic Regression 40 Cash Flow Statement 40 Contents Introduction 39 Unaudited Unaudited 39 Content Outline 39 DKKm 39 Operational Metrics 39 Sexual Satisfaction 39 Expandable Polystyrene 39 COMPARATIVE FIGURES Certain 39 Vitro Activity 39 Topics Covered Executive 39 Sleep Apnea Diagnostic 39 SELECTED INCOME STATEMENT DATA 39 Apnea Monitors 39 CALIFORNIA COASTAL COMMUNITIES INC. 39 #:#-# [031] 39 Prognostic Factors 39 Three Months Ended Nine 39 Homeostasis 39 Descriptive statistics 39 Angiographic 39 doi #.# 39 Pro Forma 39 #:#-# [029] 39 ± SEM 39 Comparability 39 Operations Unaudited 39 -0 Content Outline 39 IAS IFRS 39 FINANCIAL CONDITION AND 39 Arch Neurol 39 Cronbach alpha 39 Regulation SX 39 Statistical Supplement Operating 39 non GAAP Measures 39 NPVs 39 Transparent Conductive 39 Industrial Enzymes 39 kriging 39 Seasonal Pattern 39 Clinical Practice Guideline 39 Microplate Readers 39 Systematic Review 39 immunostaining 39 FoxP3 39 quantitive 38 Tumor Cell 38 RT qPCR 38 Variance Analysis 38 NPS PHARMACEUTICALS INC. AND 38 Bone Metastases 38 WGS# 38 Quantitative RT PCR 38 Operations Unaudited Dollars 38 Practical Applications 38 Probabilistic 38 EARNINGS Taxable equivalent 38 Univariate 38 Highly Selective 38 Six Months Ended 38 generalized estimating 38 Theory posits 38 intersegment eliminations 38 DNA Microarrays 38 Chelating Agents 38 Structure Function 38 Wechsler Memory 38 Tumor Response 38 Transcriptome 38 Sequential Quarter 38 Glycemic load 38 Mechanistic 38 SUMMARY OF QUARTERLY RESULTS 38 © Jihad Unspun 38 Dose Response 38 -0 Key 38 Applicability 38 Period Ended 38 Immunogenicity 38 Phylogenetic 38 statistical significance p 38 Quantification 38 EDWARDS LIFESCIENCES CORPORATION 38 Protein Structures 38 Overview #.#.# [002] 38 Ultrasensitive 38 Wood Preservative Chemicals 38 Adjusted 38 Fourth Qtr 38 ASC Topic #-# 38 Biosynthesis 38 - -Hector Allende 38 Toxicity Testing 38 Temperature Maps 38 Susceptibility 38 REIT Taxable 38 Normative 38 #/#/EC [001] 38 Complementarity 38 variography 38 Pearson correlation coefficient 38 Highlights Three Months 38 NOI FFO 38 Data Extraction 38 Protein Biomarker 38 pharmacodynamic parameters 38 Cardiorespiratory fitness 38 GBPm GBPm GBPm 38 Recent Accounting Pronouncements 38 Darbepoetin Alfa 38 Speciation 38 Synthesizing 38 Histopathological 38 stoichiometry 38 EN #-# [002] 38 Operations unaudited 38 Recalculation 38 Tweet Sentiments web 37 Ended - [011] 37 Epithelial Cell 37 Randomized Controlled Trials 37 FIFO gross 37 EndedDecember 37 Morphological 37 Dose Ranging 37 confidence intervals CIs 37 Condensed Consolidated 37 OTHER OPERATIONS 37 Adverse Event 37 Genotypic 37 GAAP Fully Diluted 37 Regulatory Developments 37 Intravenous Equipment 37 Cronbach 37 #Figure [003] 37 metabolite concentrations 37 B.3 37 Condensed Consolidated Cash Flow 37 Three Months Ended 37 Teratology 37 adjusted unlevered free 37 Q#/FY# 37 Feed Acidifiers 37 d dimer 37 iTRAQ 37 NORTHERN TRUST CORPORATION Supplemental 37 Supplementary Appendix 37 Study Analyzes 37 semiquantitative 37 Supplementary Information 37 unaudited Quarter Ended 37 Histopathologic 37 Markov Chain 37 Psychiatry #:#-# [002] 37 Segment Highlights 37 Adjusted EBIT 37 lanthanum carbonate 37 2nd edn 37 Cancer Incidence Mortality 37 Macroscopic 37 AUCs 37 Microstructure 37 Theological Responses 37 Provides Detailed 37 Sustained virologic response 37 Supplemental Figure 37 Ethical Considerations 37 Quarter Ended 37 Geometrical 37 Veterinary Vaccines 37 Industrial Protective Clothing 37 J Clin Oncol 37 #S rRNA 37 Predisposition 37 Digging Into 36 corresponding reconciliations 36 Brain Function 36 retest reliability 36 Equivalence 36 NSABP B 36 ANCOVA 36 NOAEL 36 Eukaryotic 36 - Aarkstore Enterprise [002] 36 J Immunol 36 GROUP RESULTS 36 Microstructural 36 * Denotes [002] 36 Ultrasound Equipment 36 Diagnosis Treatment 36 Retained Earnings Unaudited 36 Segmented Results 36 Thermodynamic 36 Signaling Pathways 36 Acrylic Resins 36 Fig. 3b 36 Orders Backlog 36 linear regression analysis 36 Trace Element 36 Link OAM 36 Managed Balance Sheet 36 enthalpy 36 Black Scholes Merton 36 - UnaudCrouppen 36 #T# L1 36 Haplotype 36 Quantifiable 36 Analytical Tool 36 Psychiatric Epidemiology 36 Geochimica et Cosmochimica Acta 36 inferential statistics 36 Genetically Engineered Animals 36 #:#-# [016] 36 microarray gene expression 36 Nambu theories permeate 36 Methods 36 Biochemical Sciences 36 Antiangiogenic 36 Prospective Randomized Trial 36 Practitioner Guide 36 Inception Date 36 #:#-# [033] 36 liquid chromatographic 36 regression coefficients 36 AVEs 36 APPENDIX 36 Correlation 36 Histologic 36 glycolytic 36 Mantel Haenszel 36 purposive approach 36 QRS width 36 Phenotypic 36 Satellite Transponders 36 blackbody 36 Interventional Cardiology Devices 36 chi squared 36 Antihypertensive 36 Condensed consolidated 36 OSIs 36 urinary N telopeptide 36 Temperature Monitoring Devices 36 serum lipid 36 Phytochemistry 36 NCES #-# 36 Pastoral Psychological 35 Lexical 35 Population Genetics 35 Quantum mechanics 35 unaudited Consolidated Statements 35 Meta analyzes 35 Statistical Methods 35 Income Statement 35 RECORD1 35 Sentinel Lymph Node Biopsy 35 Protein Expression 35 C.1 35 Gene Silencing 35 Protein Interactions 35 diffusivity 35 Factors Impacting 35 fundamental constants 35 univariate 35 Selectivity 35 Hematological Cancers 35 ABCSG 35 Condensed Historical 35 Bioperine 35 Therapeutic Monoclonal Antibodies 35 MDRD 35 RAD SVT 35 magnetic permeability 35 Sensitivity analyzes 35 Quantity kg 35 multivariate Cox 35 coating thickness 35 FOREXYARD Daily Forex 35 Unconsolidated GAAP 35 ANSI C#.# 35 #:#-#,# CrossRef Medline [002] 35 Heterogeneity 35 p.# [001] 35 Ranbaxy formulations 35 Long Lesion 35 Multiscale Modeling 35 Aspergillus nidulans 35 ordinary differential equations 35 Intervention Trial 35 multivariate statistical 35 multiple logistic regression 35 octanol 35 Toxicological 35 Non inferiority 35 Randomised 35 Adversely Affects 35 Score MOS 35 invariants 35 SF #v# 35 pairwise comparisons 35 Novel Therapeutic 35 powder diffraction 35 intraclass correlation coefficients 35 CFR Pt 35 unobservable inputs 35 Gene Ontology GO 35 Gastric Cancer 35 Carotid Endarterectomy 35 Glutamic acid 35 oxide thickness EOT 35 Prognostic 35 antineutrino 35 Comparable 35 E = mc2 35 Planck constant 35 demonstrated clinically meaningful 35 interrater reliability 35 Comparative Study 35 lattice QCD 35 Radiation Induced 35 Infectious Disease Testing 35 JESD# [002] 35 Double Blind Randomized 35 Cost Effectiveness 34 REPORTED RESULTS 34 Phylogeny 34 -Lake Andrusia 34 Segmental analysis 34 used interchangeably 34 Pearson correlation coefficients 34 Descriptive 34 Anesthesia Disposables 34 Hidden Markov 34 Bioequivalence 34 Nine Months 34 hydrodynamic radius 34 ANOVA 34 Postmenopausal Hormone Therapy 34 absorption coefficient 34 Kaplan Meier method 34 Och Ziff Funds 34 #S rRNA gene 34 Electrophysiological 34 J Rheumatol 34 Multivariable 34 Sciencein 34 logistic regression 34 Functional Outcomes 34 DCiE 34 Hedonic 34 Cervical Spine 34 ADAS cog 34 equivalence 34 eigenvalue 34 nonparametric 34 Oral Anticoagulants 34 Modifiable 34 Pharmacokinetic 34 Releases Audited 34 Getz Gilberto collaboration 34 CONSORT 34 HAQ DI 34 Pathophysiology 34 Significant Accounting Policies 34 J Virol 34 Pharmacodynamic 34 Pathologic 34 Cognitive Abilities 34 perturbation theory 34 Endometrial Cancer 34 Benchmarking Analysis 34 plasma pharmacokinetics 34 Linear regression 34 mathematical notation 34 σ 34 NIR spectroscopy 34 #:# [018] 34 BizAcumen LLC 34 COMMERCE BANCSHARES INC. 34 DIABECELL ® 34 isotherms 34 WOMAC pain 34 Einstein Podolsky Rosen 34 Markets Analyse 34 #:#-#,# [002] 34 correlation coefficients 34 ISO/IEC# 34 Schrodinger equation 34 Automotive Sensors 34 sensitivity specificity 34 Empirical Evidence 34 Solunar 34 Clinical Significance 34 Spending Patterns 34 Microbial Genome 34 Psychodynamic 34 Immunohistochemical 34 χ 34 subatomic physics 34 CRD3 33 Characterization 33 Bonferroni 33 Selected Quarterly 33 meta analytic 33 Molecular Genetic 33 reliabilities 33 Mendelian inheritance 33 Survey MEPS 33 IMS MIDAS 33 Glycemic index 33 Comparison 33 GBPm GBPm 33 penal substitution 33 EDQM 33 Overviews 33 convergent validity 33 Reloxin ® 33 Pharmacokinetic PK 33 Uterine Cancer 33 Big Bang cosmology 33 multiple linear regression 33 Disaggregated 33 DAS# scores 33 factorial 33 Multicenter 33 Appendix 33 LDL particle 33 fat saturates 33 multicenter multinational 33 immunohistochemical 33 Nanopatterning 33 See Attachment 33 intima media thickness IMT 33 #:#-# [018] 33 intraobserver 33 Attack Trial ALLHAT 33 Methodological 33 Recent Past 33 unaudited Consolidated Statement 33 Assessment Questionnaire 33 amperometric 33 MALDI-TOF/TOF 33 pp #-# 33 allele frequencies 33 Practical Aspects 33 Workplace Hazardous Materials 33 Valuation Model 33 Highest Quarterly 33 Visual Analogue Scale VAS 33 NHANES #-# 33 Pauli exclusion 33 Prognostic Value 33 quantum capacitance 33 Dietary Assessment 33 LRIC 33 LDL HDL 33 Reasonableness 33 Diagnostic Criteria 33 Multicenter Phase 33 Asset Utilization 33 Segmented 33 microdose 33 Observational Studies 33 diffusion coefficients 33 ended -David Gozal 33 Regression Analysis 33 Gene Expression 33 MERIT ES 33 Stratification 33 cUL 33 Lecturer Senior Lecturer 33 magnetisation 33 Critical Thinking Skills 33 TRIPs Agreement 33 isomers 33 Evaluative 33 Correlates 33 Months Ended -Oracle #g databases 33 tables summarize 33 Hepatocellular Carcinoma 33 ADCS ADL 33 condensed consolidated 33 Clinical Decision Making 33 regression analyzes 33 Statistical Summary 33 NOD mouse 33 Minimum Subscription 33 EN ISO # 33 Efficacy 33 Managements Discussion 33 gravitational redshift 33 lognormal 33 Equivalency 33 RTCA DO #B 32 Supplemental Schedule 32 Forced Migration 32 Quality Indicators 32 Mathematical Models 32 Pharmacopoeia 32 Monographs 32 mrad 32 CT Angiography 32 Toxicogenomics 32 IVIVC 32 QTc intervals 32 Pharmacokinetics 32 Attitudes Towards 32 Breast Carcinoma 32 Analytical Method 32 Anthropometric 32 absorbance 32 reproducible measurements 32 E = mc 32 sine cosine 32 GAAPs 32 covariance 32 IMPACT DCM 32 CORE OM 32 National Inpatient Sample 32 Myocardial Perfusion 32 Segment 32 physico chemical properties 32 Randomized trials 32 #:# [013] 32 PartnerRe Ltd. Supplementary 32 BUSINESS DESCRIPTION 32 Numerical Methods 32 ratiometric 32 apolipoproteins 32 Explanatory notes 32 Table 32 PCWP 32 Standardised 32 rev. ed 32 logarithm 32 GLOBOCAN 32 Neuropsychiatric Inventory NPI 32 Neuroanatomy 32 Symptom severity 32 Wilcoxon rank sum 32 variance ANOVA 32 eigenvalues 32 Chartered Accountants Handbook 32 Summarized 32 Primary endpoints 32 electron proton 32 Correlation coefficients 32 clinico pathological 32 #.#mg L [001]